biotech stocks to watch

It is a well-known fact that pharmaceutical companies from all over the world have been working diligently to come up with cures for different types of cancer. Although a definite cure for cancer has not been found yet, there are plenty of companies which have come up with therapies which help treat a patient considerably.

The cancer medicine industry runs into hundreds of billions of dollars in terms of value. Therefore, it may be worthwhile to look at cancer-related stocks. There could be considerable value if some companies manage to execute all their plans correctly. On that note, here is a look at three cancer-related stocks.

PharmaCyte Biotech (PMCB)

If you’re looking at PharmaCyte Biotech (PMCB) at this exact moment, you’re seeing it before the company begins clinical trials and just as it’s preparing to complete its Investigational New Drug application for the FDA.  Whether you’re new to biotech stocks or a seasoned vet, you should understand how important milestones like this are for a company.

Right now, PharmaCyte Biotech (PMCB) is putting together the necessary material for its planned clinical trial for inoperable pancreatic cancer, one of the most deadly forms of cancer today. Just to give you an idea, pancreatic cancer, in general, has the highest death rate of all major cancers. Only 9% of people with this cancer will survive more than five years [1].

Right now, PharmaCyte (PMCB) could be on the verge of a major FDA event and a potential catalyst to become the next big biotech stock to watch. This industry is experiencing remarkable innovation, and now the race is to get behind the next breakthrough.

|REPORT|IS THIS THE NEXT BIG BIOTECH BREAKTHROUGH?

Iovance Biotherapeutics (IOVA)

The first one to consider in this regard is Iovance Biotherapeutics Inc (IOVA Stock Report), which is close to coming up with a solid cancer tumor treatment and if it gets the United States Food and Drugs Administration approval, then it could be huge for the company. The medicine in question could prove to be a revolutionary one when it comes to solid cancer tumors treatment and if it manages to develop it in time, it could seek FDA approval at some point in 2020.

biotech stocks to watch Iovance (IOVA)

In addition to that, the company has revealed data that suggests that its tumor-infiltrating lymphocytes treatment approach has instigated better response most patients and that is the treatment its new medicine is going to be based on. The company is currently in the process of enrolling patients for the trial. On the other hand, the FDA stated last month that if the ongoing Phase 2 trial proves to be successful then Iovance can file for cervical cancer treatment.

|REPORT|IS THIS THE NEXT BIG BIOTECH BREAKTHROUGH?

Myriad Genetics (MYGN)

The other company to be considered is Myriad Genetics, Inc. (MYGN Stock Report), which is involved in creating customized medicines for patients who suffer from different types of cancer. It goes without saying that creating medicines that are tailored to the genetic makeup of a patient has the potential to be much more effective and there lies the attraction of such a stock.

biotech stocks to watch Myriad Genetics (MYGN)

In addition to that, the company also provides genetic screening services for cancers. It helps detect any risk of developing cancer in an individual and that is an invaluable service. At over $20 a share, it is trading below 13 times its future earnings.

|REPORT|IS THIS THE NEXT BIG BIOTECH BREAKTHROUGH?

biotech stock to watch 2019
Disclaimer: Pursuant to an agreement between MIDAM VENTURES, LLC and Complete Investment And Management LLC, a Non-affiliate Third Party, Midam was hired for a period from 07/09/2019 – 8/09/2019 to publicly disseminate information about PharmaCyte Biotech including on the Website and other media including Facebook and Twitter. We were paid $150,000 (CASH) for & were paid “0” shares of restricted common shares. We were paid an additional $150,000 (CASH) BY Complete Investment And Management LLC, a Non-affiliate Third Party, AND HAVE EXTENDED coverage for a period from 8/12/2019 – 9/12/2019. We may buy or sell additional shares of PharmaCyte Biotech in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Click Here For Full Disclaimer

EndNotes:
[1]
http://pancreatic.org/pancreatic-cancer/pancreatic-cancer-facts/

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

The $40 Billion Dollar Content Gold Rush

Apple, Disney, Netflix, Amazon, NBC, Hulu & More are All Competing Within the Global Video Streaming Market and They All Need the Same Thing…

1 Biotech Stock is Positioning Itself for Success

Biotech has always been one of the best performing sectors in the market. A number of biotech stocks have produced life-changing returns because of their treatments and opportunities. You wont believe what this 1 stock is doing…

Multi-Trillion Dollar Industry Providing Massive Opportunity in 2019 & Beyond

The most recent global report from the United Nations states that by …

What Curing Cancer & HIV Could Mean for This Company, Its Investors & The World!

The opportunity for companies within this sector is massive we are now talking about an industry that is currently worth over US$ 100 billion with the potential in the next 6.5 years to be worth over US$ 200 billion.